Company
Kardium
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
3
510(k), De Novo and PMA
Device trials
7
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
Recall records
2
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$117M
3 Form D offerings, 2010 to 2020
Equity
$1.1M
Stock sold for cash
Debt and convertible notes
$116M
$116M of it convertible
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: convertible note, $116M raised of $116M sought, first sale Dec 30, 2020, 29 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
Company details
From the company's latest Form D.
- Legal name
- Kardium Inc.
- Headquarters
- Burnaby, British Columbia, Canada
- Incorporated
- Canada (Federal Level) over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1498163 ↗
Executives, directors and promoters
As listed on the latest Form D.
5 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Kardium.
Latest FDA decisions
P240044 · Decided Aug 27, 2025 · 253 days after receipt
Device type: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation (QZI) · Cardiology
K250747 · Decided Jun 25, 2025 · 105 days after receipt
Device type: Computer, Diagnostic, Programmable (DQK) · Cardiology
K250529 · Decided Jun 3, 2025 · 99 days after receipt
Device type: Catheter, Steerable (DRA) · Cardiology
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Evaluation of the Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal Atrial FibrillationNot yet recruiting
NCT07714876 · 250 participants (planned) · Start Dec 2026 · Primary completion Dec 2029
Device: Globe Pulsed Field System · For: Paroxysmal Atrial Fibrillation
Sites: Jonesboro, Arkansas; Bellevue, Washington
NCT07651852 · 500 participants (planned) · Start Oct 9, 2026 · Primary completion Oct 2029
Device: Globe Pulsed Field System · For: Atrial Fibrillation
Sites: Jonesboro, Arkansas; Bellevue, Washington
- Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial FibrillationActive, not recruiting
NCT05462145 · 549 participants (planned) · Start Mar 9, 2023 · Primary completion Mar 2029
Device: Globe Pulsed Field System · For: Paroxysmal Atrial Fibrillation; Persistent Atrial Fibrillation
Sites: Birmingham, Alabama; Jonesboro, Arkansas; San Francisco, California · 17 sites in all
4 more trials with a free account
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0054-2013 · Started Aug 28, 2012 · Posted by FDA Oct 11, 2012
Reason given: The TORQ Sternal Closure Device, Lot 062711, is being recalled due to probability one of the metal parts may be dislodged during use.
Cause as FDA categorized it: Employee error · Device type: Twister, Wire (HXS)
Z-1973-2010 · Started Mar 31, 2010 · Posted by FDA Jul 9, 2010
Reason given: A component of the device is installed incorrectly which can result in the component falling out of the device and into the patient during use.
Cause as FDA categorized it: Other · Device type: Twister, Wire (HXS)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.